Summary of Zymeworks Conference Call Company Overview - **Company**: Zymeworks - **Industry**: Biotechnology, specifically focused on protein engineering, antibody-drug conjugates (ADCs), and T-cell engagers [1][5] Key Points and Arguments Financial Developments - Zymeworks announced a **$250 million debt financing deal** with Royalty Pharma, providing cash runway through or beyond 2028 [6][17] - The financing allows Zymeworks to retain **70% of revenues** from royalties while paying **30% to Royalty Pharma** [24][26] - The company has a strong cash position with **$270 million** in funding and **$440 million** in near-term regulatory milestones expected from partners Jazz and BeiGene [19][10] Product Pipeline and Development - **Zanidatamab (Ziihera)**: - Recently presented positive data for frontline gastric cancer and HER2 positive disease at ASCO GI, leading to a consensus peak sales estimate of **$1.1 billion to $1.2 billion**, reflecting nearly **100% growth** [14][15] - The drug showed significant improvements in overall survival (OS) and progression-free survival (PFS) [15][28] - **ADC Programs**: - Zymeworks is developing multiple ADCs, including **ZW191** (folate receptor alpha) and **ZW251** (GPC3), with ongoing dose escalation studies [12][52] - The company aims to leverage its R&D capabilities to partner with larger pharmaceutical companies while retaining downstream economics [8][16] Strategic Direction - Zymeworks is evolving into an **R&D partnership-based organization**, focusing on developing molecules for partnerships rather than commercialization [7][8] - The company is exploring opportunities in both oncology and autoimmune diseases, with a similar strategic approach for both sectors [66] Market Position and Competitive Landscape - The company believes that the **triplet regimen** (Zanidatamab combined with chemotherapy) will become the standard of care for most patients, based on physician consensus [32] - Zymeworks is actively monitoring the competitive landscape, particularly regarding other ADCs targeting the folate receptor alpha [50][82] Future Outlook - Zymeworks plans to continue its focus on **dose optimization** for its ADCs and is considering various strategic initiatives, including potential acquisitions and partnerships [20][21] - The company is committed to maintaining a strong balance sheet while exploring opportunities for stock buybacks if the stock is deemed undervalued [19][86] Additional Important Information - The company has partnerships with major pharmaceutical firms, including **Johnson & Johnson** and **GSK**, which enhance its development capabilities [17] - Zymeworks is focused on ensuring that its ADCs have strong linker stability and tolerability, which are critical for their efficacy [45][46] - The company is also exploring the potential of its **DLL3 trispecific T-cell engager** and dual cytokine blockers in autoimmune diseases, indicating a broadening of its therapeutic focus [56][62] This summary encapsulates the key points discussed during the conference call, highlighting Zymeworks' strategic initiatives, product pipeline, financial health, and market positioning.

Core Insights - Zymeworks reported regulatory approvals for zanidatamab monotherapy in Canada and the UK for second-line biliary tract cancer, with expectations for significant milestone payments from global approvals in gastroesophageal adenocarcinoma (GEA) and additional payments from partners Jazz and BeiGene [1][2] Financial Performance - Total revenue for 2025 was $106 million, an increase from $76.3 million in 2024, primarily driven by clinical and regulatory milestones [9] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, leading to a net loss of $81.1 million compared to $122.7 million in 2024 [10] Regulatory Developments - Jazz expects to submit a supplemental biologics license application (sBLA) to the FDA in Q1 2026, with zanidatamab holding Breakthrough Therapy designation for HER2-positive GEA [2] - An interim analysis for median overall survival for the zanidatamab plus chemotherapy regimen is expected by mid-2026 [3] Clinical Trials and Pipeline Updates - The Phase 3 HERIZON-GEA-01 trial showed median progression-free survival exceeding one year and median overall survival exceeding two years for zanidatamab in combination with chemotherapy [4] - Zymeworks is progressing with the Phase 1 study of ZW251, a glypican-3 antibody-drug conjugate, with plans to enroll about 100 patients [13][14] Collaboration and Financing - Zymeworks entered a $250 million non-recourse royalty-backed financing agreement with Royalty Pharma, emphasizing that this transaction is not a monetization of royalties [6][8] - The company retains milestone payments under the Jazz and BeiGene agreements, which are not used for repayment of the financing [8] Future Outlook - The company expects to fund operations beyond 2028 with existing cash resources, anticipated regulatory milestone payments, and proceeds from the royalty-backed note [11] - Adjusted gross operating expenses are projected to be about 20% lower in 2026 compared to 2025 [12]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [27] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [28][29] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [30] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under collaboration agreements [27] - The company reported regulatory approvals for zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, which is expected to translate into regulatory milestone payments of up to $440 million [12][13] Market Data and Key Metrics Changes - Consensus estimates for peak sales of zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [12] - The company expects cumulative revenue contributions through royalties and milestones to scale meaningfully as use broadens across indications and geographies [14] Company Strategy and Development Direction - The company aims to leverage a validated scaling asset to secure efficient non-dilutive capital while preserving long-term upside [16] - Zymeworks plans to deploy capital dynamically across royalty asset acquisitions and share repurchase programs, maintaining flexibility based on market conditions [24] - The company intends to integrate new partnerships and collaborations into its existing wholly owned portfolio to share funding and risk [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA [7] - The company anticipates continued discipline in capital allocation and expects adjusted gross operating expenses in 2026 to be approximately 20% lower than in 2025 [32] - Management highlighted the importance of maintaining a robust R&D operation while integrating partnerships and collaborations to enhance funding [89] Other Important Information - The company announced a strategic financing agreement with Royalty Pharma, providing $250 million of low-cost non-dilutive capital [16] - The company retains 70% of the royalty stream throughout the duration of the royalty-backed note, preserving cash flows for reinvestment [18] Q&A Session Summary Question: Regarding GPC3 ADC ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in the ZW191 program [45][48] Question: Timing of royalty-backed financing and acquisition opportunities - Management clarified that the timing for the royalty note completion was influenced by the commercialization cycle of zanidatamab and the current cost of capital [54][56] Question: Expectations for AACR and internal R&D updates - Management hinted at significant updates on both multispecifics and ADC capabilities at the upcoming AACR conference [58][60] Question: Recent data on pasritamig and its emerging profile - Management expressed enthusiasm regarding pasritamig's safety and efficacy profile, noting positive feedback from physicians [69] Question: Types of assets targeted for acquisitions and cash runway considerations - Management stated that no acquisitions are included in the cash runway forecast, emphasizing a disciplined approach to capital deployment [74][76]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [27] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [28][29] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [30] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under collaboration agreements [27] - The company reported regulatory approvals for Zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, which is expected to translate into regulatory milestone payments of up to $440 million [12][13] Market Data and Key Metrics Changes - Consensus estimates for peak sales of Zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [12] - The company expects cumulative revenue contributions through royalties and milestones to scale significantly as use broadens across indications and geographies [14] Company Strategy and Development Direction - The company aims to leverage a validated scaling asset to secure efficient non-dilutive capital while preserving long-term upside [15][16] - A strategic financing agreement with Royalty Pharma provides $250 million of low-cost non-dilutive capital, allowing for accelerated reinvestment into new value-generating assets [16][18] - The company plans to continue conducting phase 1 clinical studies for ZW191 and ZW251 in 2026, with a focus on integrating new partnerships and collaborations into its existing portfolio [36][37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding Zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA, with strong feedback from key opinion leaders [7][9] - The company anticipates significant opportunities to build financial value through regulatory approvals and milestone payments, with a cash runway extending beyond 2028 [31][32] Other Important Information - The company has approximately $270.6 million in cash resources as of December 31, 2025, down from $324.2 million in 2024 [30] - Adjusted gross operating expenses are expected to be approximately 20% lower in 2026 compared to 2025, excluding acquisition-related expenses [32] Q&A Session Summary Question: Regarding GPC3 ADC ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in ZW191 [44][46] Question: Timing of royalty-backed financing and acquisition opportunities - The timing for the royalty note completion was influenced by the commercialization cycle of Zanidatamab and the current cost of capital [52][54] Question: Types of assets targeted for acquisitions - The company is looking for innovative medicines that drive dramatic patient benefits, with a focus on oncology and immunology, but not limited to these areas [73][77] Question: Details on the 20% reduction in operating expenses and share repurchase cadence - Management confirmed that the share repurchase program is progressing well, with expectations of utilizing available capital for further repurchases as opportunities arise [84][86]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [25] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [26] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [27] - Cash resources as of December 31, 2025, were $270.6 million, down from $324.2 million in 2024 [27] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under the collaboration agreement [25] - The company reported regulatory approvals for zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, with potential milestone payments of up to $440 million for global approvals in GEA [10][11] Market Data and Key Metrics Changes - Consensus estimates for peak sales of zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [10] - The company expects cumulative revenue contributions through royalties and milestones to scale meaningfully as use broadens across indications and geographies [11] Company Strategy and Development Direction - The company aims to leverage partnerships to accelerate the development of zanidatamab and broaden its therapeutic potential while sharing development risks [7][8] - A strategic financing agreement with Royalty Pharma provides $250 million of low-cost non-dilutive capital to fund future operations and acquisitions [13][14] - The company plans to integrate new partnerships and collaborations into its existing portfolio to share funding and risk [35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA [5][6] - The company anticipates continued discipline in capital allocation and expects adjusted gross operating expenses in 2026 to be approximately 20% lower than in 2025 [30] - Management highlighted the importance of maintaining a robust R&D operation while integrating partnerships to enhance the portfolio [86] Other Important Information - The company is actively enrolling patients in the phase 1 study of ZW251, with expectations for approximately 100 patients through dose escalation [32] - The company has a cash runway extending beyond 2028, not accounting for potential acquisitions or new partnerships [72] Q&A Session Summary Question: Update on ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in ZW191 [42][47] Question: Timing of royalty-backed financing and acquisition opportunities - Management clarified that the timing for the royalty note completion was influenced by the commercialization cycle of zanidatamab and the current cost of capital [51][52] Question: Expectations for AACR and internal R&D updates - Management hinted at significant updates on multispecifics and ADC capabilities at the upcoming AACR conference [55][58] Question: Insights on pasritamig and PTK7 development - Management expressed enthusiasm for pasritamig's safety and efficacy profile, while also discussing the strategic advantages of the biparatopic design for PTK7 [62][65]

Making a meaningful difference A royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases MARCH 2026 Legal disclaimer This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forwa ...

Core Insights - Zymeworks Inc. has outlined its strategic priorities and key milestones for 2026, focusing on maximizing value creation for patients, partners, and shareholders following significant progress in 2025 [1][2] 2025 Accomplishments - The company achieved positive Phase 3 results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, with potential milestone payments of up to $440 million related to regulatory approvals in multiple regions [3][4] - Zymeworks reported cash resources of approximately $270.6 million as of December 31, 2025, which, along with anticipated milestone payments, is expected to provide a cash runway beyond 2028 [3][16][17] - A share repurchase plan of $125 million was announced to reduce share count and enhance shareholder value [3][12] Strategic Focus for 2026 - The company aims to integrate royalty growth, strategic acquisitions, and internal R&D innovation to drive long-term value creation [5][6] - Zymeworks plans to pursue partnerships and acquisitions based on strategic fit rather than immediate cash needs, emphasizing a disciplined approach to capital allocation [5][6] Clinical Development and Pipeline - Ongoing clinical studies for ZW191 and ZW251 are set to continue in 2026, with plans for future IND filings for multispecific programs [9][10] - The company anticipates presenting additional data from its clinical trials at major medical meetings in 2026 [13] Leadership and Governance - Zymeworks strengthened its leadership team and board of directors by adding experienced biotech executives [2][8] Financial Guidance - The company has outlined a disciplined framework for adjusted gross operating expenditures of approximately $300 million over three years, with a focus on cost discipline and capital allocation [15]

Core Insights - Zymeworks Inc. is actively participating in significant upcoming conferences, including the ASCO Gastrointestinal Cancers Symposium and the J.P. Morgan Annual Healthcare Conference, showcasing its innovative biotherapeutics and clinical trials [1][5]. Conference Participation - Zymeworks will present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma, at the ASCO GI Symposium on January 9, 2026 [2]. - The company will also highlight the late-breaking HERIZON-GEA-01 presentation, focusing on Ziihera® in HER2-driven gastrointestinal cancers, at the same symposium [1][3]. Presentation Details - The ZW251 presentation will be part of a multicenter study involving participants with hepatocellular carcinoma, scheduled for January 9, 2026, from 11:30 am to 1:00 pm PT [2]. - The HERIZON-GEA-01 study results will be presented on January 8, 2026, during the Oral Abstract Session A, focusing on advanced HER2-positive gastroesophageal adenocarcinoma [3]. Company Overview - Zymeworks is a biotechnology company focused on developing a diverse pipeline of multifunctional biotherapeutics aimed at improving treatment for difficult diseases, including cancer [6]. - The company utilizes its proprietary Azymetric™ technology to engineer Ziihera®, a HER2-targeted bispecific antibody, and has established partnerships for its commercialization [6].

Summary of Zymeworks FY Conference Call (December 02, 2025) Company Overview - **Company**: Zymeworks (NasdaqGS: ZYME) - **Industry**: Biotechnology Key Points and Arguments 1. **Strategic Evolution**: Zymeworks has evolved its strategy since 2022, focusing on extracting value from its IP assets without needing to build a traditional commercial entity [2][3][4] 2. **HERIZON-GEA-01 Data Impact**: The top-line data from HERIZON-GEA-01 was a significant factor in the company's strategic planning, indicating a future of excess capital and the need for thoughtful capital allocation [4][5] 3. **Integration of R&D and Royalty Portfolio**: Zymeworks aims to maintain both R&D and royalty streams within the same entity, believing that synergies exist between the two, which can drive shareholder value [5][6][10][17] 4. **Partnerships and Licensing**: The company has successfully partnered with Jazz, retaining royalties and milestones, which has proven beneficial as the market conditions improved [8][9][21] 5. **Focus on Internal Development**: Zymeworks has built a wholly owned portfolio of R&D assets, allowing for optionality in future partnerships and capital allocation [9][25] 6. **Competitive Advantage**: Zymeworks differentiates itself from traditional royalty players by having both R&D capabilities and a royalty portfolio, allowing for unique strategic maneuvers [15][17] 7. **Future Asset Development**: The company is exploring external assets for potential integration into its portfolio, leveraging its experience in capital allocation and strategy [12][13][25] 8. **Market Positioning**: Zymeworks believes it can achieve outsized returns by effectively managing its dual role as an R&D entity and a royalty organization [18][19] 9. **Potential of Rybrevant**: Rybrevant is projected to have peak sales potential between $1 billion and $5 billion, reflecting the company's confidence in its assets [22][23] 10. **ADC Development**: Zymeworks is advancing its ADC (Antibody-Drug Conjugate) assets, including ZW191, which shows promise in early data and may lead to strategic partnerships [26][28][30] Additional Important Content - **Market Perception**: The company has shifted market perception regarding its assets, particularly in gastric cancer, which was undervalued previously [21] - **Tolerability and Efficacy**: Zymeworks is focused on ensuring tolerability and efficacy in its ADCs, particularly for fragile patient populations like those with HCC (Hepatocellular Carcinoma) [34][36] - **Combination Strategies**: The company recognizes the importance of combination therapies and is open to partnerships that can enhance its competitive positioning in the market [30][31] This summary encapsulates the strategic direction, market positioning, and future plans of Zymeworks as discussed in the conference call, highlighting the company's focus on innovation and value creation in the biotechnology sector.

Business Strategy & Financial Performance - Zymeworks is transitioning to a revenue-generating organization with in-house R&D capabilities, focusing on royalty streams and strategic capital allocation for shareholder returns[6] - The company reported $103 million in revenues for 2025 as of September 30, 2025[31] - Zymeworks anticipates up to $440 million in near-term milestones from global GEA approvals for Ziihera[20, 31] - A $125 million share repurchase plan has been announced[4, 31] - Existing cash resources are expected to fund operations beyond 2028, assuming full execution of the share repurchase plan and anticipated regulatory milestone payments[2, 31, 82] Pipeline & Partnerships - Zymeworks received a $25 million regulatory milestone payment from Jazz for FDA approval of Ziihera for HER2+ (IHC 3+) BTC[4] - The company also received a $20 million milestone payment from BeOne for NMPA conditional approval of Ziihera for BTC[4] - Zymeworks recognized $25.2 million in partnership milestone payments[4] - Zymeworks has potential future milestone payments of up to $434 million from one partner and up to $1.1 billion from another, plus tiered royalties[22] Clinical Development - Initial clinical data from the Phase 1 trial of ZW191 showed a 64% overall response rate in gynecological cancers at doses ≥6.4mg/kg[42, 49] - ZW251, an ADC targeting GPC3, is in Phase 1 clinical trials for hepatocellular carcinoma (HCC)[4, 55]